Eisai sedative not approvable

A sedative Eisai gained through its acquisition of MGI Pharma has been hit with a ‘not approvable' letter from the FDA. But the pharma company says it strongly believes that further talks with the agency will lead to an approval for fospropofol disodium, which was endorsed by an FDA expert committee, with the caveat that it would like to see more data on the drug's potential impact on the obese and elderly. Release | Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.